

Metabolismo, Sistemas Modelo y Terapias para la ELA.

Tercer Encuentro Internacional de Investigación en ELA en España

Metabolism, Model Systems and Therapies for ALS.

Madrid, 2 de julio / July 2 2019

BIO

Ana Martínez

Ana Martínez is Professor at the Biological Research Institute (CIB) in Madrid. Her training was in organic chemistry and her current interest is focused in the neurodegenerative diseases, leading numerous projects on medical chemistry and rational drug design for diseases as Alzheimer, Parkinson, multiple sclerosis, spinal cord trauma and ALS.

She is working in research lines studying protein kinase and phosphodiesterase inhibitors and the searching of neurogenic drugs, with an outstanding activity in technology transference processes. As a culmination of one of those processes, since 2002 to 2007, she was R&D Director of NeuroPharma, currently known as NOSCIRA, driving to clinical assays two compounds developed in her research projects as agents modifying Alzheimer disease. She is author of more than 250 research papers, more than 30 active patents, editor of several monographic books, scientific advisor for several pharmaceutical companies and founder of the spin-off ANKAR PHARMA. Currently, she is the coordinator of the project ELA-MADRID, awarded by the Biomedicine Research Program of Comunidad de Madrid, with the main objective focused in the discovery of new drugs for the ALS treatment.